Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control

Hypertension

Volumn 66, Issue 6, 2015, Pages 1145-1151

  Polgreen, Linnea A ^a   Han, Jayoung ^c   Carter, Barry L ^a,b   Ardery, Gail P ^a   Coffey, Christopher S ^a   Chrischilles, Elizabeth A ^a   James, Paul A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c FAIRLEIGH DICKINSON UNIVERSITY   (United States)

Author keywords

blood pressure; cost benefit analysis; hypertension; pharmacists; therapy

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL PHARMACY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; HYPERTENSION; INCOME; INTERVENTION STUDY; MAJOR CLINICAL STUDY; PHYSICIAN PHARMACIST COLLABORATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TEAMWORK; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; COOPERATION; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; FEMALE; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACIST; PHYSICIAN; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COOPERATIVE BEHAVIOR; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACISTS; PHYSICIANS;

EID: 84947487364     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06023     Document Type: Article

References (35)

1. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, Hodgkinson J, Mant J, Martin U, Williams B, Wonderling D, McManus RJ. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219-1230. doi: 10.1016/S0140-6736(11)61184-7.
2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050. doi: 10.1001/jama.2010.650.
3. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307:1273-1283. doi: 10.1001/jama.2012.339.
4. World Health Organization. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. 2008. http://apps.who.int/iris/bitstream/10665/44009/1/9789241597418-eng.pdf. Accessed August 25, 2015.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665.
6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544. doi: 10.1001/jama.289.19.2534.
7. Montgomery AA, Fahey T, Ben-Shlomo Y, Harding J. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens. 2003;21:1753-1759. doi: 10.1097/01.hjh.0000084708.87421.d1.
8. Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care. BMJ. 2002;325:258-259.
9. Chobanian AV. Control of hypertension-an important national priority. N Engl J Med. 2001;345:534-535. doi: 10.1056/NEJM200108163450709.
10. Wilbur JA. Health care and the asymptomatic population. Urban Health. 1979;8:14.
11. Burnier M; 1999 World Health Organization/International Society of Hypertension Guidelines. Blood pressure control and the implementation of guidelines in clinical practice: can we fill the gap? J Hypertens. 2002;20:1251-1253.
12. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS. Clinical inertia. Ann Intern Med. 2001;135:825-834.
13. Ernst ME, Sezate GS, Lin W, Weber CA, Dawson JD, Carter BL, Bergus GR. Indication-specific 6-h systolic blood pressure thresholds can approximate 24-h determination of blood pressure control. J Hum Hypertens. 2011;25:250-255. doi: 10.1038/jhh.2010.66.
14. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ. 1995;311:293-295.
15. Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D; American Heart Association; American Society of Hypertension; Preventive Cardiovascular Nurses Association. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10-29. doi: 10.1161/HYPERTENSIONAHA.107.189010.
16. Marshall T, Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ. 2002;325:197.
17. Ogden J, Ambrose L, Khadra A, Manthri S, Symons L, Vass A, Williams M. A questionnaire study of GPs' and patients' beliefs about the different components of patient centredness. Patient Educ Couns. 2002;47:223-227.
18. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and lowdensity lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-2571. doi: 10.1001/jama.296.21.joc60162.
19. Carter BL, Ardery G, Dawson JD, James PA, Bergus GR, Doucette WR, Chrischilles EA, Franciscus CL, Xu Y. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med. 2009;169:1996-2002. doi: 10.1001/archinternmed.2009.358.
20. Carter BL, Rogers M, Daly J, Zheng S, James PA. The potency of teambased care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748-1755. doi: 10.1001/archinternmed.2009.316.
21. Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffé P, Burnier M, Burnand B, Paradis G. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000718. doi: 10.1161/JAHA.113.000718.
22. Carter BL, Coffey CS, Ardery G, Uribe L, Ecklund D, James P, Egan B, Vander Weg M, Chrischilles E, Vaughn T. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2015;8:235-243. doi: 10.1161/CIRCOUTCOMES.114.001283.
23. Houle SK, Chatterley T, Tsuyuki RT. Multidisciplinary approaches to the management of high blood pressure. Curr Opin Cardiol. 2014;29:344-353. doi: 10.1097/HCO.0000000000000071.
24. Billups SJ, Okano G, Malone D, Carter BL, Valuck R, Barnette DJ, Sintek CD. Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers. Am J Health Syst Pharm. 2000;57:29-39.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. doi: 10.1001/jama.289.19.2560.
26. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161. doi: 10.1161/01.HYP.0000150859.47929.8e.
27. Wright JT Jr, Bakris G, Greene T, et al.; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
28. Gums TH, Uribe L, Vander Weg MW, James P, Coffey C, Carter BL. Pharmacist intervention for blood pressure control: medication intensification and adherence. J Am Soc Hypertens. 2015;9:569-578. doi: 10.1016/j.jash.2015.05.005.
29. Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, Hartz AJ. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich). 2008;10:260-271.
30. Von Muenster SJ, Carter BL, Weber CA, Ernst ME, Milchak JL, Steffensmeier JJ, Xu Y. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci. 2008;30:128-135. doi: 10.1007/s11096-007-9155-6.
31. Kulchaitanaroaj P, Brooks JM, Ardery G, Newman D, Carter BL. Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control. Pharmacotherapy. 2012;32:772-780. doi: 10.1002/j.1875-9114.2012.01103.x.
32. Bruen B, Young K. Paying for prescribed drugs in Medicaid: current policy and upcoming changes. 2014. The Kaiser Commission on Medicaid and the Uninsured. https://kaiserfamilyfoundation.files.wordpress.com/2014/05/8593-paying-for-prescribed-drugs-in-medicaidcurrent-policy-and-upcoming-changes.pdf. Accessed August 25, 2015.
33. Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich). 2012;14:51-65. doi: 10.1111/j.1751-7176.2011.00542.x.
34. Staessen JA, Wang JG, Thijs L. What can be expected from optimal blood pressure control? J Hypertens Suppl. 2003;21:S3-S9.
35. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6:e1000058. doi: 10.1371/journal.pmed.1000058.